Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…